Abstract:Chimeric antigen receptor (CAR)-T cell therapy has demonstrated poor efficacy for solid tumors. The low number and poor functional persistence of CAR-T cells in tumors are the main limiting factors. Here a Chemokine-based Injectable platform for enhancing adoptive T cells' Efficacy (CITE) is presented. CITE consists of peritumorally-injected immunogel co-loading chemotactic CXCL9 particles with PD-1 antibody (aPD1) and intravenously-infused tumor-penetrating peptide iRGD. Immunogel formed drug depots and allowed sustained release of cargo peritumorally while iRGD facilitated tumor infiltration of gel-released drugs, thus remarkably increasing the amount of CXCL9 and aPD1 in the tumor. CITE induced an effective chemotactic gradient to promote the tumor-specific migration of CAR-T cells and boosted the function of infiltrated T cells by blocking immunosuppression via a two-in-one approach. Consequently, CITE yielded a 218-fold increase in the intratumoral number of transferred T cells and substantially improved the efficacies of transferred T cell receptor (TCR)-T cells and CAR-T cells in multiple syngeneic tumor models, including immunologically "cold" tumors, in immunocompetent mice. More importantly, CITE enhanced systemic antitumor immunity and elicited immune memory, enabling CITE to treat multimodal, metastatic, and recurrent tumors. CITE is broadly applicable to adoptive cell therapies involving CAR-T or TCR-T cells. The CITE (Chemokine-based Injectable platform for boosting adoptive T cells' Efficacy) system promotes the tumor-specific migration of CAR-T cells and boosts the function of infiltrated T cells via a two-in-one approach, thus substantially improving the efficacies of CAR-T cells to solid tumors. CITE also enhances systemic antitumor immunity and elicits immune memory, enabling CITE to treat multimodal, metastatic and recurrent tumors. image

CAR T Cell Membrane Camouflaged Nanocatalyst Augments CAR T Cell Therapy Efficacy Against Solid Tumor.

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming

Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment

Self-reinforcing Nano-Spearhead Drives the Efficacy of CAR-T Cells Against Progressive Triple Negative Breast Cancer

Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors

Chemokine‐Based Injectable Navigation System for Enhancing CAR‐T Cell Therapy Against Solid Tumors

Targeting the Immune-Suppressive Tumor Microenvironment to Potentiate CAR T Cell Therapy

Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells

Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice

Nanotechnology‐Based CAR‐T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy

Scattered Seeding of CAR T Cells in Solid Tumors Augments Anticancer Efficacy

Modulating Tumor Physical Microenvironment for Fueling CAR-T Cell Therapy.

Spatial Targeting of Tumor-Associated Macrophage and Tumor Cells with a Designer Nanocarrier for Cancer Chemo-Immunotherapy.

IL-12 Nanochaperone-Engineered CAR T Cell for Robust Tumor-Immunotherapy.

Enhancing CAR-T Cell Therapy Against Solid Tumor by Drug-Free Triboelectric Immunotherapy